A panel discussion on changing treatment landscape of diffuse large B-cell lymphoma (DLBCL) and how new data from ASH 2021 on CAR-T therapies and antibody-drug conjugate are likely to change frontline treatment and sequencing of therapies in relapsed and refractory DLBCL going forward.
Amivantamab Plus Lazertinib Improves PFS Irrespective of Risk in EGFR-Mutant NSCLC
BrECADD Regimen Improves PFS vs eBEACOPP Regimen in Advanced Classical Hodgkin Lymphoma
Sifting Through Data in Lung Cancer and Leukemia: Drs Levy and Saint Fleur
Updated MANIFEST-2 Data With Pelabresib/Ruxolitinib Support Paradigm Shift in Myelofibrosis
2 Commerce Drive
Cranbury, NJ 08512